...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell and Tissue Research >Mesenchymal stem cell therapy in hypertrophic and keloid scars
【24h】

Mesenchymal stem cell therapy in hypertrophic and keloid scars

机译：间充质干细胞治疗肥厚和瘢痕疙瘩

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Scars are the normal outcome of wound repair and involve a co-ordinated inflammatory and fibrotic process. When a scar does not resolve, uncontrolled chronic inflammation can persist and elicits excessive scarring that leads to a range of abnormal phenotypes such as hypertrophic and keloid scars. These pathologies result in significant impairment of quality of life over a long period of time. Existing treatment options are generally unsatisfactory, and there is mounting interest in innovative cell-based therapies. Despite the interest in mesenchymal stem cells (MSCs), there is yet to be a human clinical trial that investigates the potential of MSCs in treating abnormal scarring. A synthesis of existing evidence of animal studies may therefore provide insight into the barriers to human application. The aim of this PRISMA systematic review was to evaluate the effectiveness of MSC transplantation in the treatment of hypertrophic and keloid scars in in vivo models. A total of 11 case-control studies were identified that treated a total of 156 subjects with MSCs or MSC-conditioned media. Ten studies assessed hypertrophic scars, and one looked at keloid scars. All studies evaluated scars in terms of macroscopic and histological appearances and most incorporated immunohistochemistry. The included studies all found improvements in the above outcomes with MSC or MSC-conditioned media without complications. The studies reviewed support a role for MSC therapy in treating scars that needs further exploration. The transferability of these findings to humans is limited by factors such as the reliability and validity of the disease model, the need to identify the optimal MSC cell source, and the outcome measures employed.
机译：疤痕是伤口修复的正常结果，涉及协调的炎症和纤维化过程。当疤痕无法愈合时，不受控制的慢性炎症会持续存在，并导致过度疤痕形成，从而导致一系列异常表型，如增生性疤痕和瘢痕疙瘩疤痕。这些疾病会在很长一段时间内严重损害生活质量。现有的治疗方案通常不能令人满意，人们对基于细胞的创新疗法越来越感兴趣。尽管人们对间充质干细胞（MSCs）很感兴趣，但尚未有一项人类临床试验研究MSCs治疗异常瘢痕的潜力。因此，综合现有的动物研究证据，可以深入了解人类应用的障碍。PRISMA系统综述的目的是在体内模型中评估MSC移植治疗增生性瘢痕和瘢痕疙瘩瘢痕的有效性。共确定了11项病例对照研究，共用MSC或MSC条件培养液治疗156名受试者。十项研究评估了增生性疤痕，一项研究观察了瘢痕疙瘩疤痕。所有研究都从宏观和组织学表现以及大多数免疫组织化学方面评估了疤痕。纳入的研究均发现，使用MSC或MSC条件培养基后，上述结果均有改善，且无并发症。这些研究支持MSC疗法在治疗疤痕方面的作用，需要进一步探索。这些发现对人类的可转移性受到疾病模型的可靠性和有效性、确定最佳MSC细胞来源的需要以及所采用的结果测量等因素的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号